Literature DB >> 16102463

First clinical implant of the VentrAssist left ventricular assist system as destination therapy for end-stage heart failure.

Donald S Esmore1, David Kaye, Robert Salamonsen, Mark Buckland, Michael Rowland, Justin Negri, Yvonne Rowley, John Woodard, John R Begg, Peter Ayre, Franklin L Rosenfeldt.   

Abstract

The VentrAssist device left ventricular assist system, designed for permanent implantation, is a novel centrifugal pump with a hydrodynamically suspended rotor. The first human implant was into a 72-year-old man with New York Heart Association (NYHA) class IV heart failure due to idiopathic dilated cardiomyopathy. The implant and recovery were uneventful, and the patient survives at 17 months, is NYHA class II, and lives at home. This device shows promise in end-stage heart failure for permanent implantation and bridge to transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 16102463     DOI: 10.1016/j.healun.2005.01.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  Mechanical circulatory support.

Authors:  Deborah J Kozik; Mark D Plunkett
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

2.  Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series.

Authors:  Joseph Marsano; Jay Desai; Shannon Chang; Michelle Chau; Mark Pochapin; Grigoriy E Gurvits
Journal:  Dig Dis Sci       Date:  2015-01-24       Impact factor: 3.199

Review 3.  Bleeding with the artificial heart: Gastrointestinal hemorrhage in CF-LVAD patients.

Authors:  Grigoriy E Gurvits; Elena Fradkov
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

4.  A mock circulatory system to assess the performance of continuous-flow left ventricular assist devices (LVADs): does axial flow unload better than centrifugal LVAD?

Authors:  Thomas Sénage; Dorothée Février; Magali Michel; Emmanuel Pichot; Daniel Duveau; Steven Tsui; Jean Noel Trochu; Jean Christian Roussel
Journal:  ASAIO J       Date:  2014 Mar-Apr       Impact factor: 2.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.